论文部分内容阅读
目的研究CD40、人乳头瘤病毒(HPV)、血管内皮细胞生长因子(VEGF)及CD34在不同宫颈组织上的表达及其对宫颈癌肿瘤血管生成的影响。方法收集239例子宫颈组织标本及临床病理资料,其中正常子宫颈组织38例,慢性宫颈炎43例,宫颈上皮内瘤变(CIN)102例,宫颈鳞状上皮癌标本56例。采用免疫组织化学链霉菌抗生素蛋白过氧化物酶连接(SP)法检测不同宫颈组织中CD40、HPV16/18-E6、VEGF的表达以及以CD34抗体检测宫颈癌的微血管密度(MVD)。结果 CD40分子、HPV16/18-E6、VEGF和CD34+MVD在宫颈癌中均为高表达,与正常宫颈组织及慢性宫颈炎组织相比,差异均有统计学意义(均P<0.05)。CD40分子的在宫颈癌组织中的表达与HPV16/18-E6、VEGF以及CD34+MVD的表达成正相关(P<0.01或<0.05)。CD40分子在宫颈癌中的表达和肿瘤有无淋巴结转移、肿瘤肌层浸润深度亦成正相关(P<0.01或<0.05)。结论 CD40分子在宫颈癌肿瘤发生、发展过程及肿瘤血管的生成中起着一定的作用;CD40分子在宫颈癌组织上的表达不仅为研究肿瘤的临床进展提供了参考指标,同时也为宫颈癌的肿瘤生物学治疗提供了一靶分子。
Objective To investigate the expression of CD40, human papillomavirus (HPV), vascular endothelial growth factor (VEGF) and CD34 on different cervical tissues and their effects on angiogenesis of cervical cancer. Methods 239 cases of cervical tissue specimens and clinicopathological data were collected, including 38 cases of normal cervical tissue, 43 cases of chronic cervicitis, 102 cases of cervical intraepithelial neoplasia (CIN) and 56 cases of cervical squamous cell carcinoma. The expression of CD40, HPV16 / 18-E6 and VEGF in different cervical tissues was detected by immunohistochemical Streptomyces antibiotic protein peroxidase (SP) method and the microvessel density (MVD) of cervical cancer by CD34 antibody was detected. Results CD40, HPV16 / 18-E6, VEGF and CD34 + MVD were all highly expressed in cervical cancer, which were significantly different from those in normal cervix and chronic cervicitis (all P <0.05). The expression of CD40 in cervical cancer tissues was positively correlated with the expression of HPV16 / 18-E6, VEGF and CD34 + MVD (P <0.01 or <0.05). The expression of CD40 in cervical cancer was also positively correlated with tumor metastasis and depth of myometrial invasion (P <0.01 or <0.05). Conclusion CD40 plays an important role in carcinogenesis, development and angiogenesis of cervical cancer. The expression of CD40 on cervical cancer not only provides a reference index for studying the clinical progress of cervical cancer, Tumor biology provides a target for molecular therapy.